Fig. 8: The positive correlation between the levels of USP24 and PD-L1 in animal and clinical specimens. | Cell Death & Differentiation

Fig. 8: The positive correlation between the levels of USP24 and PD-L1 in animal and clinical specimens.

From: USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy

Fig. 8

The relevance among prognosis and several related proteins, including E2F4, E2F1, LC3-II, ULK1, ABCG2, PD-L1 and CD3 in EGFRL858R*USP24WT and EGFRL858R*USP24C1695A drug resistant mice was studied by IHC (A) and IB (B(a)), and then the levels of the indicated protein were quantitated after three independent experiments (B(b)). C The levels of PD-L1 and USP24 in clinical lung cancer patients were studied by IHC with anti-PD-L1 and anti-USP24 antibodies (a), and the correlation of USP24 levels and PD-L1 levels in early-stage of lung cancer (b), and late-stage of lung cancer (c) was show here. D The working model of how targeting USP24 prevents drug resistance during lung cancer therapy. The statistical analysis was performed by one way ANOVA; **p < 0.01, ***p < 0.005.

Back to article page